| Literature DB >> 21304505 |
José A Gómez-Puerta1, Xavier Bosch.
Abstract
In patients with active rheumatoid arthritis despite therapy with DMARDS, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?Entities:
Mesh：
Substances：
Year: 2011 PMID： 21304505 DOI： 10.1038/nrrheum.2011.8
Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543